Medigen Biotechnology Corp. (TPEX:3176)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
31.90
+0.05 (0.16%)
Apr 2, 2025, 1:30 PM CST
-17.68%
Market Cap 4.44B
Revenue (ttm) 1.37B
Net Income (ttm) -204.69M
Shares Out 139.31M
EPS (ttm) -1.47
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 65,061
Average Volume 138,215
Open 31.80
Previous Close 31.85
Day's Range 31.65 - 32.15
52-Week Range 29.50 - 48.20
Beta 0.55
RSI 29.83
Earnings Date Mar 28, 2025

About Medigen Biotechnology

Medigen Biotechnology Corp., a biopharmaceutical company, engages in the research and development of new drugs and vaccines, cytotherapy, advanced nucleic acid testing, generic drugs, aesthetic medicine, and vaccine-related products in Taiwan. It offers cell therapies, such as MAGICELL-NK, which are natural killer cells; and MAGICELL-GDT, which are T cells. It also develops OBP-301 that has completed Phase I clinical trials in combination with esophageal cancer in Japan; is in Phase I clinical trials in combination with immune checkpoint inhibi... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1999
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 3176
Full Company Profile

Financial Performance

In 2024, Medigen Biotechnology's revenue was 1.37 billion, an increase of 18.57% compared to the previous year's 1.16 billion. Losses were -204.69 million, -63.53% less than in 2023.

Financial Statements

News

There is no news available yet.